Joseph P. Erinjeri

8.6k total citations · 2 hit papers
165 papers, 4.0k citations indexed

About

Joseph P. Erinjeri is a scholar working on Pulmonary and Respiratory Medicine, Hepatology and Oncology. According to data from OpenAlex, Joseph P. Erinjeri has authored 165 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 58 papers in Hepatology and 54 papers in Oncology. Recurrent topics in Joseph P. Erinjeri's work include Hepatocellular Carcinoma Treatment and Prognosis (58 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (17 papers). Joseph P. Erinjeri is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (58 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (17 papers). Joseph P. Erinjeri collaborates with scholars based in United States, China and France. Joseph P. Erinjeri's co-authors include Stephen B. Solomon, Constantinos T. Sofocleous, Timothy W.I. Clark, Karen T. Brown, Thomas A. Woolsey, Anne M. Covey, Lynn A. Brody, Mithat Gönen, Elena N. Petre and George I. Getrajdman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Joseph P. Erinjeri

158 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone

2016 271 citations Karen T. Brown, Richard Kinh Gian et al. Journal of Clinical Oncology profile →
EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

2024 93 citations Riccardo Lencioni, Masatoshi Kudo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph P. Erinjeri United States	30	1.5k	1.2k	1.1k	809	753	165	4.0k
Sunyoung Lee South Korea	32	1.3k 0.9×	932 0.8×	528 0.5×	784 1.0×	710 0.9×	173	4.9k
Mijin Yun South Korea	41	563 0.4×	1.3k 1.1×	1.9k 1.7×	2.0k 2.5×	1.7k 2.2×	285	6.4k
Nikolaos Kelekis Greece	35	669 0.5×	577 0.5×	1.2k 1.0×	1.2k 1.5×	1.1k 1.4×	254	4.5k
Mi‐Sook Kim South Korea	30	693 0.5×	492 0.4×	901 0.8×	437 0.5×	694 0.9×	124	2.9k
Sherko Kümmel Germany	37	330 0.2×	2.5k 2.0×	814 0.7×	1.0k 1.3×	465 0.6×	227	5.0k
Hiromichi Ito Japan	37	949 0.6×	2.7k 2.2×	1.6k 1.4×	382 0.5×	2.1k 2.8×	267	5.5k
Holger Amthauer Germany	40	949 0.6×	1.5k 1.2×	1.6k 1.4×	2.5k 3.1×	1.1k 1.5×	260	5.9k
Kenji Nakamura Japan	35	1.5k 1.0×	516 0.4×	1.2k 1.0×	261 0.3×	1.5k 2.0×	232	5.0k
Shigeru Kiryu Japan	30	709 0.5×	434 0.4×	465 0.4×	1.8k 2.2×	584 0.8×	125	3.6k
Masayoshi Inoue Japan	36	299 0.2×	1.4k 1.1×	2.1k 1.8×	412 0.5×	1.2k 1.6×	254	5.0k

Countries citing papers authored by Joseph P. Erinjeri

Since Specialization

Citations

This map shows the geographic impact of Joseph P. Erinjeri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph P. Erinjeri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph P. Erinjeri more than expected).

Fields of papers citing papers by Joseph P. Erinjeri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph P. Erinjeri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph P. Erinjeri. The network helps show where Joseph P. Erinjeri may publish in the future.

Co-authorship network of co-authors of Joseph P. Erinjeri

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph P. Erinjeri. A scholar is included among the top collaborators of Joseph P. Erinjeri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph P. Erinjeri. Joseph P. Erinjeri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Petre, Elena N., Erica S. Alexander, Vlasios S. Sotirchos, et al.. (2025). Hepatocellular Carcinoma Growth Kinetics and Outcomes After Transarterial Embolization: A Single-Center Analysis. Cancers. 17(20). 3346–3346.

Alexander, Erica S., Olivier Chevallier, Vlasios S. Sotirchos, et al.. (2025). Outcomes following microwave ablation of 669 primary and metastatic lung malignancies. European Radiology. 36(3). 2295–2304. 1 indexed citations

Zadeh, Mahdi Zirakchian, Vlasios S. Sotirchos, Assen S. Kirov, et al.. (2024). Three-Dimensional Margin as a Predictor of Local Tumor Progression after Microwave Ablation: Intraprocedural versus 4–8-Week Postablation Assessment. Journal of Vascular and Interventional Radiology. 35(4). 523–532.e1. 12 indexed citations

Chan, Stephen L., Bruno Sangro, Masatoshi Kudo, et al.. (2024). Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4122–4122. 4 indexed citations

Green, Angela, Qin Zhou, Alexia Iasonos, et al.. (2024). A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.. Journal of Clinical Oncology. 42(16_suppl). 5511–5511. 4 indexed citations

Budhu, Sadna, Kwanghee Kim, Wesley Yip, et al.. (2024). Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model. Frontiers in Oncology. 14. 1405486–1405486.

Vakiani, Efsevia, Sho Fujisawa, Mithat Gönen, et al.. (2021). Immunofluorescence Assay of Ablated Colorectal Liver Metastases: The Frozen Section of Image-Guided Tumor Ablation?. Journal of Vascular and Interventional Radiology. 33(3). 308–315.e1. 5 indexed citations

Deipolyi, Amy R., Christopher Johnson, Joseph P. Erinjeri, & Yolanda Bryce. (2020). Combination Therapies with Y90: Immunoradiation. 4(4). 382–388. 2 indexed citations

Zhang, Yachao, Dae‐Hee Kim, Hooman Yarmohammadi, et al.. (2020). Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. Sarcoma. 2020. 1–8. 5 indexed citations

10.

Erinjeri, Joseph P., Achiude Bendet, Elena N. Petre, et al.. (2020). Utilization of integrated angiography-CT interventional radiology suites at a tertiary cancer center. BMC Medical Imaging. 20(1). 114–114. 5 indexed citations

11.

Ziv, Etay, Yiru Zhang, Ines Nikolovski, et al.. (2020). NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. Radiology. 297(1). 225–234. 18 indexed citations

12.

Erinjeri, Joseph P., et al.. (2020). 4:03 PM Abstract No. 334 Reduction of unplanned late hours in inpatient procedure scheduling by forecasting with the Facebook Prophet algorithm. Journal of Vascular and Interventional Radiology. 31(3). S151–S152. 1 indexed citations

13.

Haroun, Reham R., Keith Quencer, Joseph P. Erinjeri, Ryan O’Hara, & G Fine. (2019). Percutaneous Cryoablation of an Extra-Abdominal Desmoid Tumor Abutting the Skin Surface and Peritoneum. Journal of Vascular and Interventional Radiology. 30(3). 426–427. 3 indexed citations

14.

Deipolyi, Amy R., et al.. (2019). Cryoablation of a Symptomatic Chest Wall Desmoid Tumor Underneath a Silicone Breast Implant. SHILAP Revista de lepidopterología. 2019. 1–3. 1 indexed citations

15.

Erinjeri, Joseph P., G Fine, Gosse J. Adema, et al.. (2019). Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper. Radiology. 292(1). 25–34. 53 indexed citations

16.

Borgheresi, Alessandra, Anne M. Covey, Hooman Yarmohammadi, et al.. (2019). Embolization with microspheres alone for hepatocellular carcinoma with portal vein tumor: analysis of outcome and liver function at disease progression. HPB. 22(4). 588–594. 3 indexed citations

17.

Gu, Yangkui, Govindarajan Srimathveeravalli, Li‐Qun Cai, et al.. (2018). Pirfenidone inhibits cryoablation induced local macrophage infiltration along with its associated TGFb1 expression and serum cytokine level in a mouse model. Cryobiology. 82. 106–111. 10 indexed citations

18.

Getrajdman, George I., Anne M. Covey, William Alago, et al.. (2018). Push versus pull gastrostomy in cancer patients: A single center retrospective analysis of complications and technical success rates. Diagnostic and Interventional Imaging. 99(9). 547–553. 13 indexed citations

19.

Ulaner, Gary A., David M. Hyman, Dara S. Ross, et al.. (2016). Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using ⁸⁹Zr-Trastuzumab PET/CT. Journal of Nuclear Medicine. 57(10). 1523–1528. 144 indexed citations

20.

D’Angelo, Sandra P., Alexander N. Shoushtari, Mary Louise Keohan, et al.. (2016). Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research. 23(12). 2972–2980. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact